Coexistence HBsAg/HBcAC, Clinical Characterístics & Outcomes

• Conditions: Hepatitis B

• Registration Number: NCT05446532
• Lead Sponsor: Corporacion Parc Tauli

Brief Summary

HBV infection is a dynamic process with complex interactions between virus replication and the host's immune response. The appearance of anti-HBs after HBV infection generally indicates recovery and immunity to HBV1 infection. However, there are several published studies that describe the coexistence of the marker of chronic infection (HBsAg +) and the marker of functional cure (HBsAc +). There are contradictory studies on whether the coexistence of HBsAg/HBsAc implies a different clinical course.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-06-15
• Study First Submitted: 2022-06-29
• Status Verified: 2022-07
• Study First Submitted QC: 2022-07-05
• Last Update Submitted: 2022-07-05
• Study First Posted: 2022-07-06
• Last Update Posted: 2022-07-06
• Primary Completion: 2022-10-31
• Study Completion: 2022-12-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• all those patients who have been seen in outpatient hepatology consultations and who present positive HBsAg and HBsAc serology simultaneously.

Exclusion Criteria

• Hepatitis C or HIV Co-infection

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
prevalence concomitant HBsAg and HBsAc markers	10 years	To describe the prevalence of concomitant HBsAg and HBsAc markers in our area

Secondary Outcome Measures

Name	Time	Method
differences between immunocompetent patients with respect to immunocompromised ones.	10 years	To compare if there are differences in the prevalence or clinical outcome according if the patient has any degree of immunosupresion or not.

Trial Locations

Locations (1)

H. Consorci Sanitari Parc Tauli; 🇪🇸 Sabadell, Barcelona, Spain